Document is current
Any future updates will be listed below
-
Authors
Marshall, Helen S. https://orcid.org/0000-0003-2521-5166
Molina, Jean-Michel https://orcid.org/0000-0001-8684-2214
Berlaimont, Valérie https://orcid.org/0000-0003-3850-4477
Mulgirigama, Aruni https://orcid.org/0000-0003-4777-7098
Sohn, Woo-Yun https://orcid.org/0000-0002-4034-4735
Berçot, Béatrice https://orcid.org/0000-0003-1603-3635
Bobde, Shravani https://orcid.org/0009-0006-9480-5521
- License Information
-
More Information
Article History
Received: 28 June 2024
Accepted: 21 October 2024
First Online: 27 November 2024
Declarations
:
: Author HSM is an investigator on clinical trials sponsored by Industry including Iliad, Pfizer, Moderna, and Seqirus. Author HSM’s institution receives funding for sponsored studies from GSK, Pfizer, Sanofi-Pasteur. Author HSM receives no personal funding from Industry. Authors SB, AM, VB, and WS are employees of GSK and may hold stock or stock options. Author SB holds patents on antimicrobial peptides and related methods issued prior to employment at GSK and before this work began. Author JM has received institutional grants and personal fees for advisory boards from Gilead, Helix, and Merck. Author BB declares no financial or non-financial competing interests.
